Limit processed foods, sugary snacks, and high-fat items to support steady energy and weight
Several mid-stage trials will read out in 2025 to provide important proof points for novel MoAs and their potential for differentiation, e.g., Lillys bimagrumab (activin/myostatin type II receptor inhibitor) in combination with semaglutide, aiming to deliver weight loss while preserving muscle mass (phase 2b)
Amrica Latina Perspectiva de Mercado : En Amrica Latina, la demanda de suplementos para el control del peso y relacionados con la diabetes est en aumento, con ms consumidores buscando productos que apoyen la regulacin del azcar en sangre
This suppresses appetite, delays gastric emptying, and promotes glucose-dependent insulin secretion
This suggests that GLP-1R-Gs activation rescues insulin secretion inhibited by pasireotide through the activation of SSTRs-Gi in GLP-1R-MIN-6 cells (Fig